Hims & Hers shares soar premarket; Pfizer, Agilent Technologies slip

Hims & Hers Health stock surged after a report indicated Novo Nordisk plans to sell weight-loss drugs through its platform, despite a recent legal dispute. Meanwhile, Pfizer and Agilent Technologies saw their shares decline due to clinical trial results and an acquisition announcement, respectively. The broader U.S. stock futures also fell amid escalating Middle East conflict driving up energy prices.